A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

B. A. Wilky, M. A. Rudek, S. Ahmed, D. A. Laheru, D. Cosgrove, R. C. Donehower, B. Nelkin, D. Ball, L. A. Doyle, H. Chen, X. Ye, G. Bigley, C. Womack, N. S. Azad

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences